NeoStem (AMEX:NBS): Pro-Active Research Initiates as Spec Buy

Written by Mike Havrilla

Thursday, 04 June 2009 07:07

NeoStem, Inc. (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insurance for possible use in later years or to address an emerging medical need. Pro-Active Research Group initiated coverage of NeoStem on 5/27/09 with a speculative buy rating and $5/share long-term price target. The PDF report is available to view or download for free at the BioMedReports.com stock research reports section. The following are investment highlights outlined in the NeoStem report: (1) it is the first company to offer adult stem cell collection and banking services to general adult population; (2) leadership team includes executives with extensive medical, scientific, and business experience; (3) recently concluded an $11 million financing for strategic growth initiatives in China and U.S.; (4) poised to become leader in medical tourism for wounds, orthopedics, and regenerative medicine; (5) recently announced licensing deals for adult stem cell based, regenerative medicine technologies; (6) rated speculative buy with long-term price target of $5/share (about $100M fully diluted market cap); and (7) positive news flow expected along with growth initiatives in China to fuel continued stock price gains.

The following are links to eight YouTube videos listed as favorites on my channel related to NeoStem and promising uses of adult stem cells, including (1) an interview with NeoStem's CEO, Robin Smith; (2) peripheral vascular disease; (3) multiple sclerosis (MS); (4) orthopedic surgery; (5) diabetes; (6) heart attack; (7) heart valve development; and (8) lupus.

Disclosure: No positions.

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

Add this page to your favorite Social Bookmarking websites